{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:30:17Z","timestamp":1791498617699,"version":"4.3.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A <jats:italic>post-hoc<\/jats:italic> analysis of a single-arm interventional clinical trial on apixaban treatment of cancer patients with VTE to investigate whether the occurrence of any of the endpoints could be associated with the concurrent use of an interacting drug. Drugs taken by the patients during the trial period were categorized as either increasing bleeding risk, increasing thrombosis risk, both or neither.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>298 patients were divided into groups based on whether they used no interacting drugs (controls, n=74), drugs increasing bleeding risk (n=55), drugs increasing thrombosis risk (n=8), or both (n=161). Odds ratios (OR) were calculated for recurrent VTE, clinically relevant non-major bleeding (CRNMB), and major bleeding during the 36-month follow-up period. Each patient took a median of 13 different drugs over the study period. 67% of the patients used drugs expected to both increase bleeding and thrombosis. The use of fluconazole appeared associated with CRNMB (OR 3.6, 95% confidence interval (CI) 0.99-13), but not with major bleeding (OR 0.56, 95% CI 0.06 - 4.8). Non-steroid anti-inflammatory drugs were not associated with CRNMB (OR 1.0, 95% CI 0.25-4.1) or major bleedings (OR 0.72, 95% CI 0.14 - 3.6). Use of antiplatelet therapy was not associated with CRNMB (OR 0.75, 95% CI, 0.22 - 2.58) or major bleeding (OR 0.2, 95% CI, 0.02-1.6). There were no major bleedings in 23 patients using aprepitant nor in the 10 patients taking macrolides. We found no association between drugs and recurrent VTE, except that there were no recurrent VTE in 19 patients using bevacizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite the high number of drugs taken that could potentially interact with apixaban, none were found to clearly influence clinical outcomes, except that fluconazole may increase the risk of CRNMB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1520725","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:14:45Z","timestamp":1737954885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism"],"prefix":"10.3389","volume":"15","author":[{"given":"Marte","family":"Svalastoga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine-Lise","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorunn","family":"Brekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone","family":"Enden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege","family":"Fr\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herish","family":"Garresori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Marie","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Carmen","family":"Porojnicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Hansen","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Torfoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin Osvik","family":"Velle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde Skuterud","family":"Wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Morten","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Erik Astrup","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk\u00a0factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Internal Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active Malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"New\u00a0Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood advances"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Disposition"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug\u2013drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinetics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats","volume":"26","author":"O'Connell","year":"2021","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction","volume":"313","author":"Olsen","year":"2015","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00733.x","article-title":"Tamoxifen and risk of idiopathic venous thromboembolism","volume":"45","author":"Meier","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"20","author":"Hanigan","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.10.004","article-title":"The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies","volume":"231","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.08.042","article-title":"Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism","volume":"196","author":"Hannevik","year":"2020","journal-title":"Thromb Res"},{"key":"B19","article-title":"Guidance for industry: clinical drug interaction studies\u2014cytochrome P450 enzyme-and transporter-mediated drug interactions","volume-title":"Center for drug evaluation and research","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.150580","article-title":"Bleeding associated with coadministration of rivaroxaban and clarithromycin","volume":"188","author":"Fralick","year":"2016","journal-title":"Cmaj"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140","article-title":"Anticoagulation SoCo. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemostasis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Thrombosis SCotISo, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb haemostasis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.2013.76.issue-3","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/phar.v42.12","article-title":"Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk","volume":"42","author":"Cid","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.1835","article-title":"Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants","volume":"180","author":"Hill","year":"2020","journal-title":"JAMA Internal Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15692","article-title":"Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism","volume":"20","author":"Bistervels","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3593","article-title":"Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function","volume":"3","author":"Pham","year":"2020","journal-title":"JAMA network Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/1078155216631408","article-title":"Drug interactions with aprepitant or fosaprepitant: review of literature and implications for clinical practice","volume":"23","author":"Dushenkov","year":"2017","journal-title":"J\u00a0Oncol Pharm Practice"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"Jama"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v11.8","article-title":"Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER-Medicare analysis","volume":"11","author":"Ades","year":"2022","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a\u00a0nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Internal Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v193.6","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br J haematology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319503","article-title":"Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants","volume":"108","author":"Holt","year":"2022","journal-title":"Heart"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1520725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:14:48Z","timestamp":1737954888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1520725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1520725"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1520725","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1520725"}}